IGC Pharma, Inc. (IGC)

IGC Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	-7.12	-13	-11.51	-15.02	-8.81
Depreciation & Amortization	0.62	0.64	0.66	0.65	0.48
Loss (Gain) From Sale of Assets	-0.03	-0.04	0.04	-	-
Asset Writedown & Restructuring Costs	0.15	3.45	-	0.83	-
Loss (Gain) From Sale of Investments	-	-	-	0.05	0.17
Stock-Based Compensation	1.64	1.77	2.84	2.2	0.66
Provision & Write-off of Bad Debts	0.01	0.09	0.13	1.72	-
Other Operating Activities	-	-	-	-0.43	-
Change in Accounts Receivable	-0.01	-0.03	0.01	0.05	-0.04
Change in Inventory	0.18	1.01	0.9	1.93	-1.23
Change in Accounts Payable	0.11	0.24	-0.45	0.5	-0.29
Change in Other Net Operating Assets	-0.35	0.67	0.34	0.05	-1.73
Operating Cash Flow	-4.8	-5.2	-7.05	-7.46	-10.8
Capital Expenditures	-0.11	-0.14	-0.31	-0.24	-1.47
Sale of Property, Plant & Equipment	0.04	0.04	0.54	0.03	-
Sale (Purchase) of Intangibles	-0.37	-0.38	-0.31	-0.54	-0.12
Investment in Securities	-	0.15	-0.15	-	4.98
Investing Cash Flow	-0.44	-0.32	-0.24	-0.74	3.39
Long-Term Debt Issued	-	-	-	-	0.53
Total Debt Issued	-	-	-	-	0.53
Long-Term Debt Repaid	-0	-0	-0	-0	-
Total Debt Repaid	-0	-0	-0	-0	-
Net Debt Issued (Repaid)	-0	-0	-0	-0	0.53
Issuance of Common Stock	4.45	3.53	0.1	4.14	14.16
Financing Cash Flow	4.45	3.52	0.1	4.14	14.69
Foreign Exchange Rate Adjustments	-0.01	-0.01	-0.08	-0.03	0.02
Net Cash Flow	-0.79	-2	-7.26	-4.09	7.29
Free Cash Flow	-4.91	-5.34	-7.36	-7.7	-12.27
Free Cash Flow Margin	-386.07%	-396.80%	-807.57%	-1939.04%	-1366.37%
Free Cash Flow Per Share	-0.06	-0.09	-0.14	-0.15	-0.29
Levered Free Cash Flow	-4.46	-3.17	-3.37	-2.47	-9.21
Unlevered Free Cash Flow	-4.46	-3.17	-3.37	-2.47	-9.21
Change in Net Working Capital	-0.06	-1.06	-0.99	-4.58	3.3

Updated Jun 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q